ADCC Expression Cell Line
The ADCC+ Cell Line is designed for rapid identification of clones expressing high levels of recombinant therapeutic proteins.
The ADCC+ Cell Line
PerkinElmer’s antibody-dependent cellular cytotoxicity (ADCC)+ Cell Line is an expression cell line for the company’s Horizon Discovery CHOSOURCE platform, which is designed for rapid identification of clones expressing high levels of recombinant therapeutic proteins.
The ADCC+ cell line eliminates the fucose gene to increase ADCC activity with the intent of improving the potency and efficacy of therapeutic antibodies and fusion protein biotherapeutics. At the same time, it aims to reduce dosage requirements and side effects for patients.
Drug Solutions Podcast: Processing Equipment Trends
November 1st 2022In this episode, Alivia Leon, assistant editor, speaks with Christian Dunne, director of global corporate business development, Chargepoint Technology, about current and future processing equipment trends, such as automation, cost, and sustainability.
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
